Biosig Technologies (NASDAQ:STEX) Director Purchases $75,900.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Director Morgan Lee Lekstrom purchased 23,000 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was bought at an average cost of $3.30 per share, for a total transaction of $75,900.00. Following the completion of the acquisition, the director directly owned 71,000 shares in the company, valued at $234,300. The trade was a 47.92% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, January 29th, Morgan Lee Lekstrom acquired 2,500 shares of Biosig Technologies stock. The shares were bought at an average price of $3.70 per share, with a total value of $9,250.00.
• On Tuesday, January 27th, Morgan Lee Lekstrom acquired 5,500 shares of Biosig Technologies stock. The stock was bought at an average cost of $3.12 per share, for a total transaction of $17,160.00.
• On Friday, January 23rd, Morgan Lee Lekstrom bought 41,000 shares of Biosig Technologies stock. The stock was bought at an average price of $3.13 per share, for a total transaction of $128,330.00.

Biosig Technologies Stock Down 11.6%

Biosig Technologies stock opened at $3.34 on Friday. Biosig Technologies, Inc. has a twelve month low of $0.40 and a twelve month high of $14.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings began coverage on Biosig Technologies in a research report on Friday, January 23rd. They set a “sell (d-)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.